El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 

Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy

dc.contributor.authorWeinhofer, Isabelle
dc.contributor.authorRommer, Paulus
dc.contributor.authorGleiss, Andreas
dc.contributor.authorPonleitner, Markus
dc.contributor.authorZierfuss, Bettina
dc.contributor.authorWaidhofer Söllner, Petra
dc.contributor.authorFourcade, Stéphane
dc.contributor.authorGrabmeier Pfistershammer, Katharina
dc.contributor.authorReinert, Marie Christine
dc.contributor.authorGöpfert, Jens
dc.contributor.authorHeine, Anne
dc.contributor.authorYska, Hemmo A. F.
dc.contributor.authorCasasnovas, Carlos
dc.contributor.authorCantarín, Verónica
dc.contributor.authorBergner, Caroline G.
dc.contributor.authorMallack, Eric
dc.contributor.authorForss Petter, Sonja
dc.contributor.authorAubourg, Patrick
dc.contributor.authorBley, Annette
dc.contributor.authorEngelen, Marc
dc.contributor.authorEichler, Florian
dc.contributor.authorLund, Troy C.
dc.contributor.authorPujol, Aurora, 1968-
dc.contributor.authorKöhler, Wolfgang
dc.contributor.authorKühl, Jörn Sven
dc.contributor.authorBerger, Johannes
dc.date.accessioned2025-12-15T09:38:13Z
dc.date.available2025-12-15T09:38:13Z
dc.date.issued2023-09-07
dc.date.updated2025-12-04T13:37:26Z
dc.description.abstractBackground X-linked adrenoleukodystrophy (X-ALD) is highly variable, ranging from slowly progressive adreno-myeloneuropathy to severe brain demyelination and inflammation (cerebral ALD, CALD) affecting males with childhood peak onset. Risk models integrating blood-based biomarkers to indicate CALD onset, enabling timely interventions, are lacking. Therefore, we evaluated the prognostic value of blood biomarkers in addition to current neuroimaging predictors for early detection of CALD.Methods We measured blood biomarkers in a retrospective, male CALD risk-assessment cohort consisting of 134 X-ALD patients and 66 controls and in a phenotype-blinded validation set (25 X-ALD boys, 4-13 years) using Simoa (R) and Luminex (R) technologies.Findings Among 25 biomarkers indicating axonal damage, astrocye/microglia activation, or immune-cell recruitment, neurofilament light chain (NfL) had the highest prognostic value for early indication of childhood/adolescent CALD. A plasma NfL cut-off level of 8.33 pg/mL, determined in the assessment cohort, correctly discriminated CALD with an accuracy of 96% [95% CI: 80-100] in the validation group. Multivariable logistic regression models revealed that combining NfL with GFAP or cytokines/chemokines (IL-15, IL-12p40, CXCL8, CCL11, CCL22, and IL-4) that were significantly elevated in CALD vs healthy controls had no additional benefit for detecting neuroinflammation. Some cytokines/chemokines were elevated only in childhood/adolescent CALD and already upregulated in eBioMedicineasymptomatic X-ALD children (IL-15, IL-12p40, and CCL7). In adults, NfL levels distinguished CALD but were lower than in childhood/adolescent CALD patients with similar (MRI) lesion severity. Blood GFAP did not differentiate CALD from non-inflammatory X-ALD.Interpretation Biomarker-based risk prediction with a plasma NfL cut-off value of 8.33 pg/mL, determined by ROC analysis, indicates CALD onset with high sensitivity and specificity in childhood X-ALD patients. A specific pro -inflammatory cytokine/chemokine profile in asymptomatic X-ALD boys may indicate a primed, immanent inflammatory state aligning with peak onset of CALD. Age-related differences in biomarker levels in adult vs childhood CALD patients warrants caution in predicting onset and progression of CALD in adults. Further evaluations are needed to assess clinical utility of the NfL cut-off for risk prognosis of CALD onset.
dc.format.extent14 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn2352-3964
dc.identifier.pmid37683329
dc.identifier.urihttps://hdl.handle.net/2445/224901
dc.language.isoeng
dc.publisherElsevier BV
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.ebiom.2023.104781
dc.relation.ispartofEBioMedicine, 2023, vol. 96, 104781
dc.relation.urihttps://doi.org/10.1016/j.ebiom.2023.104781
dc.rightscc-by (c) Weinhofer, Isabelle et al., 2023
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.classificationTrastorns del metabolisme dels lípids
dc.subject.classificationMalalties neurodegeneratives
dc.subject.classificationAlfa-sinucleïna
dc.subject.otherLipid metabolism disorders
dc.subject.otherNeurodegenerative Diseases
dc.subject.otherAlpha-synuclein
dc.titleBiomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
PIIS235239642300347X.pdf
Mida:
1.34 MB
Format:
Adobe Portable Document Format